Business
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma GlobeNewswire July 16, 2024
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma GlobeNewswire July 16, 2024
Related
Share this page